Last edition
News about "futility analysis"
argenx Updates Phase 3 UNITY Trial of Efgartigimod
argenx plans to stop its phase 3 UNITY study of efgartigimod SC in Sjögren’s disease following an IDMC recommendation based on interim analysis.
Futility Analysis | 09/10/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members